<ol class="cite-this-references"><li id="reference-A866">Staines AG, Coughtrie MW, Burchell B: N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J Pharmacol Exp Ther. 2004 Dec;311(3):1131-7. Epub 2004 Aug 3. [<a href="/articles/A866" target="_blank">Article</a>] </li><li id="reference-A867">Sisodiya SM, Goldstein DB: Drug resistance in epilepsy: more twists in the tale. Epilepsia. 2007 Dec;48(12):2369-70. [<a href="/articles/A867" target="_blank">Article</a>] </li><li id="reference-A180301">Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi MR: A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. J Res Med Sci. 2013 Mar;18(Suppl 1):S81-5. [<a href="/articles/A180301" target="_blank">Article</a>] </li><li id="reference-A180304">Marino SE, Birnbaum AK, Leppik IE, Conway JM, Musib LC, Brundage RC, Ramsay RE, Pennell PB, White JR, Gross CR, Rarick JO, Mishra U, Cloyd JC: Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther. 2012 Mar;91(3):483-8. doi: 10.1038/clpt.2011.251. Epub 2012 Jan 25. [<a href="/articles/A180304" target="_blank">Article</a>] </li><li id="reference-A180310">Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP: Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002 Feb;27(1-2):121-30. [<a href="/articles/A180310" target="_blank">Article</a>] </li><li id="reference-A180319">Chen CH, Lin SK: Carbamazepine treatment of bipolar disorder: a retrospective evaluation of naturalistic long-term outcomes. BMC Psychiatry. 2012 May 23;12:47. doi: 10.1186/1471-244X-12-47. [<a href="/articles/A180319" target="_blank">Article</a>] </li><li id="reference-A180397">Johnson DL, Gellman H, Waters RL, Tognella M: Brachioradialis transfer for wrist extension in tetraplegic patients who have fifth-cervical-level neurological function. J Bone Joint Surg Am. 1996 Jul;78(7):1063-7. doi: 10.2106/00004623-199607000-00011. [<a href="/articles/A180397" target="_blank">Article</a>] </li><li id="reference-A180403">Kuo CC, Chen RS, Lu L, Chen RC: Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from phenytoin and possible therapeutic implications. Mol Pharmacol. 1997 Jun;51(6):1077-83. doi: 10.1124/mol.51.6.1077. [<a href="/articles/A180403" target="_blank">Article</a>] </li><li id="reference-A180415">Barrons R, Roberts N: The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome. J Clin Pharm Ther. 2010 Apr;35(2):153-67. doi: 10.1111/j.1365-2710.2009.01098.x. [<a href="/articles/A180415" target="_blank">Article</a>] </li><li id="reference-A180421">Aurora RN, Kristo DA, Bista SR, Rowley JA, Zak RS, Casey KR, Lamm CI, Tracy SL, Rosenberg RS: The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012 Aug 1;35(8):1039-62. doi: 10.5665/sleep.1988. [<a href="/articles/A180421" target="_blank">Article</a>] </li><li id="reference-A180424">Rawlins MD, Collste P, Bertilsson L, Palmer L: Distribution and elimination kinetics of carbamazepine in man. Eur J Clin Pharmacol. 1975 Feb 28;8(2):91-6. [<a href="/articles/A180424" target="_blank">Article</a>] </li><li id="reference-A180427">Yoshimura R, Yanagihara N, Terao T, Minami K, Toyohira Y, Ueno S, Uezono Y, Abe K, Izumi F: An active metabolite of carbamazepine, carbamazepine-10,11-epoxide, inhibits ion channel-mediated catecholamine secretion in cultured bovine adrenal medullary cells. Psychopharmacology (Berl). 1998 Feb;135(4):368-73. [<a href="/articles/A180427" target="_blank">Article</a>] </li><li id="reference-A180436">Thorn CF, Leckband SG, Kelsoe J, Leeder JS, Muller DJ, Klein TE, Altman RB: PharmGKB summary: carbamazepine pathway. Pharmacogenet Genomics. 2011 Dec;21(12):906-10. doi: 10.1097/FPC.0b013e328348c6f2. [<a href="/articles/A180436" target="_blank">Article</a>] </li><li id="reference-A180439">Lv Y, Zheng X, Shi M, Wang Z, Cui L: Different EPHX1 methylation levels in promoter area between carbamazepine-resistant epilepsy group and carbamazepine-sensitive epilepsy group in Chinese population. BMC Neurol. 2019 Jun 4;19(1):114. doi: 10.1186/s12883-019-1308-4. [<a href="/articles/A180439" target="_blank">Article</a>] </li><li id="reference-T634">Jasdave S. Maan; Abdolreza Saadabadi (2019). Carbamazepine. Stat Pearls Publishing. </li><li id="reference-L1335">FDA Approved Drug Products: EQUETRO (carbamazepine) extended-release capsules [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf" target="_blank">Link</a>] </li><li id="reference-L7195">Pharm KGB, carbamazepine pathway, pharmacokinetics [<a href="https://www.pharmgkb.org/pathway/PA165817070" target="_blank">Link</a>] </li><li id="reference-L7156">Carbamazepine MSDS [<a href="https://www.caymanchem.com/msdss/15422m.pdf" target="_blank">Link</a>] </li><li id="reference-L7216">ipolar Disorders and Carbamazepine: Pharmacokinetics,Pharmacodynamics, Therapeutic Effects and Indications of Carbamazepine: Review of Articles [<a href="https://www.omicsonline.org/open-access/bipolar-disorders-and-carbamazepine-pharmacokineticspharmacodynamics-therapeutic-effects-and-indications-ofcarbamazepine-review-of-2472-095X-1000112.php?aid=79291" target="_blank">Link</a>] </li><li id="reference-L11121">FDA Approved Drug Products: Tegretol (carbamazepine) [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016608s115_018281_s058_018927s055_020234_s047.pdf" target="_blank">Link</a>] </li><li id="reference-L38274">FDA Approved Drug Products: CARNEXIV (carbamazepine) injection [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206030s002lbl.pdf" target="_blank">Link</a>] </li><li id="reference-L9713">FDA Approved Drug Products: Carbatrol (carbamazepine) extended-release capsules for oral use [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020712s037lbl.pdf" target="_blank">Link</a>] </li></ol>